Fig 1: Immunohistochemical analysis of the key FRGs in the FRS model. High TNFSF14 expression, low JAM2, HGF, and SPN expression were associated with poor prognosis in patients with LUAD. (A) Immunohistochemical analysis of the intensity of TNFSF14 staining in tumors from 50 patients with lung adenocarcinoma and Kaplan-Meier analysis of the correlation between H-scores of immunohistochemistry for TNFSF14 and the survival cycle of patients with LUAD; (B) Immunohistochemical analysis of the intensity of HGF staining in tumors from 50 patients with lung adenocarcinoma and Kaplan-Meier analysis of the correlation between H-scores of immunohistochemistry for HGF and the survival cycle of patients with LUAD. (C) Immunohistochemical analysis of LFR staining intensity in tumors from 50 lung adenocarcinoma patients, Kaplan-Meier analysis of H-scores of immunohistochemistry for LFR correlated with the survival cycle of LUAD patients; (D) Immunohistochemical analysis of JAM2 staining intensity in tumors from 50 lung adenocarcinoma patients, Kaplan-Meier analysis of JAM2 H-scores of immunohistochemistry correlated with the survival cycle of LUAD patients; (E) immunohistochemistry analyzed the intensity of SPN staining in the tumors of 50 lung adenocarcinoma patients, and Kaplan-Meier analyzed the correlation of H-scores of immunohistochemistry of SPN with the survival cycle of LUAD patients.